Nufarm Limited (NUF) Earnings Call Transcript & Summary
November 16, 2021
Earnings Call Speaker Segments
Operator
operatorWe appreciate everyone being on the line, and we're glad to have you join us for Nufarm Limited's FY '21 results call. <<operator_script>> At this point, I'll turn things over to Mr. Greg Hunt, our Managing Director and CEO. Please proceed.
Gregory Hunt
executiveThanks, Melanie, and good morning, everyone. Welcome, and thank you for being with us today. Before we begin today's presentation, I'd like to point you to the disclaimer on Page 2, especially the part covering forward-looking statements. I'm joined here today — here in Melbourne with our CFO, Paul Townsend, who came on board — he joined Nufarm earlier in the 2021 financial year. We're also joined by Brent Zacharias, Group Executive of our Nuseed business, and many of you will know him, of course, and he's with us from Canada to discuss the Seed Technologies results. I'm pleased to say that 2021 has been a successful year for Nufarm. Although COVID continues to create challenges for our industry, the fundamental economic driver and the fundamental challenge of growing more food to meet the needs of growing populations remains intact. And with better seasonal conditions across all of our markets, we've seen strong demand for seeds and for crop protection products this year. The impact of COVID on Nufarm has been somewhat at the margin. And safety is, of course, our most critical priority, and the additional measures we put in place to keep our people safe have allowed us to maintain production largely without disruption.
Gregory Hunt
executiveSeveral of our sites hit notable safety landmarks this year. Rather than naming each one, they're all visible on the slide before you. That said, I do want to highlight the renewal of our major hazard facility licenses here in Victoria. That matters a great deal, since it mirrors both the effort and the capital we've put into process safety management across the past 5 years. We've driven a systemic cultural change and a shift in safety throughout the whole company, and not only within Australia, and that provides the proper basis for ensuring all of our colleagues get home safely each day. Turning to how COVID affected us operationally and financially, global supply chains have taken the biggest hit. Agriculture is only one among many sectors facing supply delays along with steep rises in sea freight and logistics costs. Nufarm hasn't been spared either, yet our solid financial results partly demonstrate the investment we've directed into our supply chain to put boots on the ground in China. Our procurement team in Shanghai is well-credentialed and experienced. Their work building long-term supply relationships instead of transactional buy/sell arrangements has stood us in good stead through these turbulent times.
Gregory Hunt
executiveAt the half-year results, we also noted that COVID had led to a steep decline in U.S. salmon demand, which did hold back first-half sales of our omega-3 Aquaterra product. Despite that temporary setback, adoption of this technology across the industry is progressing steadily, and our customer base keeps growing. We're now seeing signs that salmon demand is recovering as the U.S. comes out of pandemic-related restrictions, and Brent will go into that in more detail shortly. Removing restrictions in the U.S. has also boosted demand for our U.S. turf and ornamental products, and that business is back at more normal operating levels. Another effect of tight supply and logistics challenges has been a shift in how our earnings are weighted. At the half-year results, we noted that COVID-related disruptions and supply risk were altering customer buying patterns, with sales locked in earlier than usual. That weighted EBITDA more heavily toward the first half. And while that is unusual, this pattern of early buying appears set to carry on into 2022, with supply conditions still tight and channel inventories at historically low levels. Turning to the financial results.
Gregory Hunt
executiveLike I mentioned before, this has been a good year, and we delivered a strong financial outcome. Revenue rose 10% to $3.2 billion, while underlying EBITDA climbed 51% to $370 million. NPAT of $61 million marks a swing back from last year's loss, and our cash generation keeps getting better — it's a real highlight of this result. Our balance sheet now sits in a far stronger spot than it has for many years. That, combined with better cash generation and the positive outlook we hold for financial year '22, gave the Board the confidence to reinstate the dividend, declaring $0.04 per share for the final dividend. Paul will walk you through the specifics of the dividend and capital management policy changes later in this presentation. All in all, I'm pleased with our progress and the financial result. We've delivered against the priorities we set for the year. Our safety culture keeps improving. Margins and cash generation have both improved. We hit the targets we set for the performance improvement program. We've brought back a sustainable earnings capability in our European business, and the acquired portfolio is, pleasingly, contributing a meaningful percentage of the earnings recovery. Positive earnings and momentum carry on in APAC and North America, and we've hit major milestones that will drive value from our Seed Technologies platforms.
Gregory Hunt
executiveGladly, on Slide 7 you'll notice that all regions helped drive the 51% EBITDA increase versus a year ago. Our newly formed APAC region gained from robust demand amid better seasonal conditions and strong commodity prices, which pushed volumes higher. Industry supply was constrained, and often we managed to deliver product in situations where competitors could not. Now that the drought headwinds are behind us, the payoff from our restructuring work in recent years is showing up more clearly, with higher revenues flowing through to the bottom line and to cash generation. North America likewise gained from better seasonal conditions and elevated commodity prices, and together with the easing of COVID restrictions, that fueled stronger demand for our products. Our team has done a superb job of using our manufacturing assets to capture business even with the highly challenging supply disruptions the industry faced in this region. In Europe, we achieved a very substantial earnings increase relative to the growth in revenues. The key earnings drivers were the performance improvement program, a better product mix, and the normalization of raw material supply and pricing for the acquired portfolios. As I said earlier, resetting Europe's earnings base was a top priority this year, and the European team has performed excellently.
Gregory Hunt
executiveTurning to Seed Technologies, we posted robust growth momentum in this year as well, helped by better grain prices for canola and sunflower, which drove solid demand throughout the base seeds portfolio. Adoption of our proprietary hybrid products has been good, and that is pushing revenue and earnings higher. We're quite happy with the earnings improvement this year, but sustainable, consistent returns matter a great deal to us. Over the short to medium term, diversifying both our product portfolio and our geographic footprint is a major mitigant against earnings volatility. A lot of you will be aware that herbicide products growers require every single year carry heavy weight in our portfolio, and they are complemented by a smaller share of higher-margin insecticide and fungicide products, where demand tends to be more volatile. That mix has given us a good balance over the last few years, and we've put investment into more differentiated, higher-margin products that complement our portfolio of foundational lower-margin products. On geographic diversity, our footprint has shifted considerably following the sale of the South American business. Even so, we keep a strong presence in key markets where we think we can stay relevant to our customers and produce good cash returns.
Gregory Hunt
executiveWe anticipate that expansion in our Seed Technologies business will help broaden where our revenue comes from over the years ahead. I want to use this opportunity to offer a few remarks about sustainability. Agriculture's footprint on worldwide ecosystems must be brought down, and we are acting at present so we can satisfy what our customers and stakeholders will need down the road. It's important to point out that our crop protection products deliver answers to several of the biggest sustainability challenges. Population growth is placing growing strain on the world, and crop protection products assist in getting the most out of crop productivity. Such products additionally assist farmers in addressing climate change by means of minimum and no-till farming. That cuts fuel emissions on the farm and raises soil carbon, and all of this contributes to resilience against dry weather conditions. We have tightened our attention on cutting emissions and pledged to a 30% decrease in Scope 1 and 2 greenhouse gas emissions from our manufacturing sites by 2030. We anticipate reaching this via a mix of operational efficiency and contracts for renewable energy. We also began reporting climate-related risk this year, and next year we will report under the TCFD framework.
Gregory Hunt
executiveOur sustainability work has also been mapped against the United Nations sustainable development goals, which helps sharpen where we concentrate our contribution to the wider industry — the wider industry objective of lowering agriculture's impact. We think we are positioned well both to add to and gain from this industry imperative. Our new seed business rests on a beyond-yield strategy centered on creating new solutions from plant-based products. The most advanced sustainable solution we have is Omega-3 canola oil. By complementing canola oil and fish oil in salmon feed, it helps safeguard marine environments and curb overfishing. Carinata, our latest investment, tackles the demand for more sustainable fuel sources by storing carbon in soils and yielding a nonfood oil that serves as a feedstock for biofuel production. Within our crop protection business, product development is increasingly aimed at managing resistance, identifying effective approaches to lower chemical application rates, and growing our portfolio of alternative products for farms. In Europe this year, we introduced our new Bio brand, which unites our biological product portfolio and lets growers more easily locate the right biological solution through a digital platform. We are additionally making early-stage investments that we expect will broaden our range of additions to our traditional chemistry crop protection in the years ahead.
Gregory Hunt
executiveAmong the investments are CROP.ZONE, Enko, plus R&D work carried out with universities and research bodies including the CSIRO. Further details on that are going to be included in the sustainability report we put out later this year. With that said, I'll pass things over to Paul now so he can walk through the financials in a bit more depth. Paul?
Paul Townsend
executiveThanks, Greg, and good morning, everyone. Before we begin today, I want to point out that because our fiscal year-end has changed, many of the comparative figures we will go over are pro forma numbers. A more detailed analysis of performance against the statutory comparative period can be found in the materials posted with IAS <<inaudible>>. I would also like to flag that we have made sales of $198 million at 0 margin to Sumitomo in Latin America under the transitional supply agreement. And where appropriate, the impact of this has been excluded from our commentary and figures. Moving to Slide 13. Disciplined expense management, together with favorable FX translation benefits, has produced a year-on-year improvement in the SG&A cost position. It is pleasing to report that the company has delivered on its $25 million annualized cost reduction commitment under this program. As you can see on the chart, the $20 million released under this program has helped mitigate cost pressures that Nufarm has endured with respect to freight and warehousing expenses associated with COVID-19 and Brexit, with North America and Europe mainly being impacted. Travel and other savings related to COVID-19 restrictions has also offset safety provisions.
Paul Townsend
executiveWe remain on schedule to realize the benefits we previously reported — roughly $10 million to $15 million — tied to shutting down the 2,4-D plant in Linz as well as the Raymond Road insecticide and fungicide facility. Those benefits ought to come through over the course of 2022 year as inventory is unwound. Moving to Slide 14. Over the year, we finished a review of how our capital is structured along with our capital management principles. The broad purpose behind that review was making sure we grasped the different cyclical cash flow scenarios that Nufarm faces, and to layer on a capital structure and funding platform that supports financial resilience across the cycles. That in the end lowers Nufarm's balance sheet risk and lifts liquidity levels. We anticipate this will additionally foster discipline in cost and capital management throughout the business, alongside a mindset of continuous improvement toward net working capital management, since that matters greatly for driving a sustainable operating cash flow position for Nufarm. Our capital management framework supplies the foundation for capital allocation decisions, including how free cash flow is applied. Nufarm is meant to take a cascading approach to using free cash flow for these operations in the following manner: first, direct free cash flow toward investment growth projects and/or small bolt-on acquisitions where projected returns meet internal return on funds support measures that exceed Nufarm's weighted average cost of capital.
Paul Townsend
executiveSecond, we look at paying the dividend in connection with free cash flow, provided we stay within the statutory core target leverage range of a maximum of 1.5x to 2x as we adopt the new dividend policy. And last, we consider returning any excess capital to shareholders when Nufarm sits below its leverage metric thresholds and growth opportunities available are insufficient. Such capital return steps could involve special dividends as well as share buybacks. The Board has changed the dividend policy so that far greater attention goes to generating cash, particularly managing net working capital, and to keeping an appropriate capital structure for the group. Moving now to Slide 15. This chart, I believe, makes the point on its own as it lays out the different cash flow movements that produced the $257 million result. Clearly, EBITDA and the net working capital inflow are the main contributors. On working capital, the principal factors are better customer collections and lower inventory, while payable days worsened slightly. Utilization of the supplier financing facility rose over the year, mainly because raw material prices increased. That facility stays an important part of strengthening Nufarm's ties with key Chinese raw material suppliers, which help secure product supplies amid today's tight market conditions.
Paul Townsend
executiveTax and interest payments came in at $31 million and $55 billion, beating expectations, while CapEx investment of roughly $147 million is below expectations because of timing issues affected by COVID-19 restrictions. To get to a net cash flow figure for the group, payments under the Nufarm step-up securities of about $10 million must be subtracted from the total, giving a net inflow of $247 million. All in all, an excellent cash flow result for the company. As I said earlier, Nufarm competes in an industry that is very working capital-intensive, so actively managing net working capital matters a great deal when it comes to delivering acceptable returns to shareholders. During 2019 and 2020, weak seasonal conditions, especially in Australia, along with disrupted supply chains in Europe, caused working capital on the balance sheet to build up. Across the last 12 to 18 months, we have seen this position unwind significantly, and the chart on the left shows that average net working capital of sales now sits at 34%, ahead of our target range of 35% to 40% — a pleasing outcome for Nufarm. This focus will continue and must be balanced against ensuring continuity of supply given the global logistics and supply chain challenges.
Paul Townsend
executiveWhen it comes to capital expenditure, the chart on the right shows the difference between what we invest in property, plant and equipment versus intangibles. Total CapEx spending is below the roughly $180 million we previously communicated, which we highlighted at the half year results, and it's mainly tied to reduced property, plant and equipment outlays, such as timing-related issues stemming from COVID-19 restrictions. Alongside property, plant investment — which is mostly maintenance CapEx for the Australian business — there are significant growth investments in spending on new teams, in new products and in product innovation, spanning both the crop protection and seeds business units. For 2022, CapEx expense is projected at $190 million, with approximately $35 million of that going to new growth projects across the manufacturing plants. This spending forms part of a wider investment program spanning the next 1 to 3 years. Return on funds employed as of 30 September stood at 5.9%. Finally, turning to the balance sheet on Slide 17. As you can see, debt and leverage have shifted significantly following the sale of our South American businesses on 1 April last year. Leverage sits at 0.9x EBITDA, below our maximum core leverage target of 1.5 to 2x, including leases.
Paul Townsend
executiveAt year-end, liquidity remains quite robust, with roughly $600 million in undrawn facilities and cash balances exceeding $700 million. And lastly, after reviewing our capital structure and given these strong financial results, we're now well positioned to look at refinancing options, subject of course to market conditions. Back to you, Greg, for more detail on regional performance.
Gregory Hunt
executiveNow let's go through each of our business segments in detail. The APAC region posted a really strong year. The headwinds we faced over the past 3 years have finally become tailwinds. With higher revenues, better margins and reduced SG&A costs, we delivered a 47% rise in EBITDA. This newly formed region is made up of our businesses in Australia, New Zealand, the Cropland spraying equipment business here in Australia, Indonesia and our operations in Malaysia, which support sales into other Southeastern countries. It also takes in our joint venture in China. Australia and New Zealand matter a great deal to us. They're our home base, and we hold leading market positions in both of these markets. Many of you will be familiar with the restructuring we've carried out in these countries over the last 5 years. We've shut 5 factories, merged 2 brands into 1 and taken costs out of both back and front office. And over the last 2 years, the benefit of this restructuring work has been skewered by the impact of the drought, better return to seasonal conditions. And in the case of financial year '21, probably better than normal conditions lets us showcase the true value of this business. EBITDA from the legacy ANZ business came to $82 million this year, and this result highlights the leverage of this business, not just to the downside, but also the upside from improved seasonal conditions.
Gregory Hunt
executiveIn these markets, we get really robust backing from our channel partners as well as from end-use customers. We feel it matters to keep sovereign manufacturing capability, and the essential part we play, so that farmers can count on a dependable supply and a wide range of products made and formulated locally for growing their crops. Now that the reset of our manufacturing footprint and the back office is finished, our attention has shifted to growing the portfolio. For the domestic market, we brought out several new tailored products, among them Crucial®, Terrad'or® and Saracen®, and every one of them made a positive contribution to the FY '21 result. We are likewise collaborating with local institutions, including the CSRI and the Queensland University, on continued product development to support Australian growers, and we anticipate commercialization of these products within the next 2 to 3 years. EBITDA of $30 million came from the legacy Asia business, where higher sales volumes and lower SG&A costs more than offset the hit from unfavorable currency translation. By combining the Asia and the ANZ businesses, we aim to leverage our manufacturing footprint further across this region and to reprioritize growth opportunities in Asia. Since the Asia Pacific region accounts for the biggest share of the global population, we see opportunities to build further on our existing presence there.
Gregory Hunt
executiveMoving on to Europe now. As I said before, one of our main priorities for this year was resetting the earnings base there, and we've achieved the turnaround in earnings we were aiming for, with EBITDA rising 80% in local currency to EUR 108 million. That brings profitability back to where it stood in 2019 and represents a solid first step toward better returns. The earnings improvement came from better availability and lower raw material costs for insecticides and thumbicides, along with higher volumes, a better product mix, and reduced SG&A costs. We're also seeing higher sales from the acquired portfolios. And although separating the earnings of those portfolios from the rest of the business is becoming harder, they added roughly EUR 62 million, or about 57% of the earnings in euro terms. It's a solid result, but there is certainly more work to do. We've made substantial investments in this region over the past 3 years, and the current return doesn't justify that investment. I'm aware that the farm <<inaudible>> ambitions of a 50% reduction in crop chemicals and 25% production from organics by 2030 are a concern for me. Still, those ambitions also create opportunities for us.
Gregory Hunt
executiveThe money we’ve put into the portfolios we acquired, our stake in CROP.ZONE, setting up the new buyout, and our tie-up with Sumitomo along with their proprietary products — these are all key pieces of the current European business that will let us capture these opportunities. CROP.ZONE is a tech firm based in Germany that has come up with a hybrid electric weed control solution. We’ve been collaborating with them for a while, and during the year we formalized a very modest equity investment in the company. Even though it’s just a small investment, I’m mentioning it to make the point that we’re aiming to build greater awareness of the alternative solutions across our European portfolio. As I said, we recently rebranded our biologicals portfolio in Europe so that the alternative options are clearer to farmers. In the near term, the existing portfolio can sustain the current earnings, assuming normal seasonal conditions, despite the regulatory headwinds. While we expect industry-wide supply chain disruptions and the costs tied to them to keep having an impact into 2022, we believe we’re well placed to handle these issues. Turning to North America, our North American business has come back strongly from the historical flood since last year. In U.S.
Gregory Hunt
executiveIn dollar terms, revenue rose 19% and EBITDA climbed 25%, which mirrors the fundamental expansion in the item that was skewed upward last year. Across every part of the business segment, the North American team achieved volume gains, with revenues higher in crop protection across the U.S., Canada, and Mexico. As COVID restrictions eased, especially during the second half of the year, the turf and ornamental business likewise came back to more typical conditions and typical volumes. Channel inventories in North America sit at their lowest levels in quite a while, a situation that mainly mirrors the global and domestic supply disruption affecting the whole industry this year. Our earnings growth mirrors the payoff from what we invested in domestic manufacturing capacity and logistics within this region. Customers are rewarding us for reliability. Although we could not satisfy every bit of possible demand, we have preserved our customers' confidence through what has been an extremely tough stretch for them on the supply side. Product is beginning to move more freely in October and November, especially out of China, yet domestic port availability remains difficult. We hold enough inventory either on hand or on the water to cover the majority of our first half demand plan.
Gregory Hunt
executiveI'm going to hand things over to Brent now so he can talk through how the Seed Technology segment performed.
Brent Zacharias
executiveThanks, Brent. Thanks, Greg, and good morning, everyone. The Seed Technologies segment covers results of our new seat business and the sale of seed treatment chemistry. The full year results showed strong growth from the prior comparative period. Segment revenue rose 21% to $241 million, and underlying EBITDA climbed 57% to $46 million, reflecting improved margins. The key drivers of this performance were higher sales of canola hybrid seed in Australia, increased sales of higher-margin sorghum and sunflower products in the U.S. and South America, and increased second half sales of Aquaterra and omega-3 canola oil to Chilean Aquaterra customers. The seed treatment contribution was slightly down on the prior 12 months, with lower sales in Europe and APAC partially offset by a solid initial performance from the newly launched Trunemco products in North America. As the pie chart on the slide illustrate, the change in Nufarm's financial year now captures the majority of both segment revenues and earnings in the first 6 months of the period, coinciding with the major selling season of our core seeds portfolio. Turning to the next slide. Our R&D pipeline investment over recent years is delivering clear benefits as we gain strong grower support for our better performing canola, sorghum and sunflower hybrids.
Brent Zacharias
executiveFresh canola varieties in Australia are producing meaningful yield gains, and our canola footprint across the Americas is expanding nicely. We'll bring new sunflower products to market in every key region, several of them carrying multiple trade technologies. We're picking up share in sorghum too, thanks to launches of new early maturity hybrids along with hybrids that deliver other agronomic advantages. Turning to the omega-3 canola platform: as we noted at the half, COVID-19 hit food service demand for salmon, and as a result sales to our Aquaterra Chilean agriculture customers came in below expectations. On an encouraging note, salmon demand has recovered during the second half, which fed through into stronger orders through the latter portion of the reporting period and growth in our customer base. Customers also tell us they're having a positive experience using Aquaterra in their feed and farm operations. Having paused commercial plant use of omega-3 canola in the U.S. during financial year '21, we intend to restart production in 2022. We also hit important milestones in developing an omega-3 canola oil for human nutrition markets, to be sold under the Nutriterra name. The FDA recognized Nutriterra as a new dietary ingredient, and a human clinical trial produced important results showing both safety and efficacy.
Brent Zacharias
executiveThese results are proven pivotal as we continue discussions with potential commercial partners. And over the last twelve months, both Aquaterra and Nutriterra, we see sustainability certification by Friends of the Sea, which is a preeminent certification standard for products and services that respect and protect the marine environment. And finally, a quick update on our carinata business platform. We see carinata is another of our Value Beyond Yield technologies and is being developed as a drop in feedstock for low-carbon biofuels. It is a nonfood covered crop that provides our contract growers with an additional source of revenue on existing farm line while protecting and improving soil health for their primary crop rotations. Carinata Oil is suitable for processing into renewable diesel for co-processing, and has now been certified by the International Civil Aviation Organization as an eligible feedstock for sustainable aviation fuel. This certification includes the default carbon life cycle reduction value similar to used cooking oil. Each step of our crop production is independently audited and certified to standards established by the Roundtable on Sustainable Biomaterials, known as RSB. With increased interest from potential offtake partners, we have scaled up production in Argentina and commenced development testing in other markets ahead of further expansion plans.
Brent Zacharias
executiveLooking ahead to the next calendar year, we'll bring to market a new carinata hybrid commercially, and that hybrid is showing substantial gains in yield. We expect additional exciting progress connected to our carinata platform, and to our Value Beyond Yield technologies more broadly, across the coming 12 months. At this point I'll turn things back over to Greg.
Gregory Hunt
executiveThanks, Brent. The past few months have brought some very encouraging developments, and those really strengthen our confidence in what the seeds business can deliver for the group over the long term. Before we turn to the outlook, let me spend a minute recapping what our priorities are for the new financial year. Our strategy hasn't changed: better cash generation and returns remain the financial priority. We're growing volumes so we can build scale and a global footprint. We're improving margins by widening our portfolio and product mix. We're investing in supply chain efficiency and cutting our cost base. With the South American business sold, we've refocused on those regions where we think we can produce the strongest cash flows. Ultimately, better returns are what we're focused on. Higher earnings from the asset base we already have will lift returns in the short term, along with a disciplined approach to pursuing current growth investments and new investments that will deliver improved future returns. Now, on to the outlook. While we aren't providing guidance, grain prices still look positive, and favourable seasonal conditions in the grain producing regions relevant to Nufarm are driving continued strong demand for crop protection products.
Gregory Hunt
executiveRising prices for raw materials, together with difficulties in global logistics and supply chains, are going to keep squeezing margins. Even so, we anticipate that higher prices and growth in volume will offset part of that. Demand has stayed strong through October and November. Because supply remains tight and channel inventories sit at historically low levels, we are likely to see sales happen sooner than usual, since customers want to lock in supplies. Following the change to our financial year-end, the seeds business now generates most of its earnings during the first half. Stronger prices for canola, sorghum and sunflower are fueling very robust seed demand, and this business will benefit — or rather, the base seeds business will benefit. As we discussed, with the salmon market improving, we expect wider adoption of Aquaterra, and therefore we plan to restart commercial plannings of omega-3 canola in calendar year 2022. Underlying market trends support growing demand for carinata as a low carbon fuel stock, and we plan to expand commercial plannings of carinata in calendar year 2022. To sum up, we have produced a solid result that leaves the headwinds of the past 2 years behind us. We are starting to see the value of the steps we have taken to reshape our business.
Gregory Hunt
executiveFinancial year '22 has begun for us with robust trading conditions and results throughout every one of our business segments. So on that note, Melanie, I'll return the floor to you, and we can open things up for some questions.
Operator
operator<<operator_script>> The initial question is from Grant Saligari at Credit Suisse.
Grant Saligari
analystWell done on those results. The profit rebound across Europe is especially encouraging to see. I suppose my question concerns the regulatory picture in Europe, with a particular focus on product registrations. It seems a few significant actives are still awaiting approval from the European Commission. And then in the U.K., as far as our portfolio goes, reregistrations are needed for your CPA-based products along with several others. So I realize that's a long lead-in, but what I'd like to understand is roughly what share of your revenue is up for reregistration in FY '22. And then, taking a somewhat longer view across the next 3 years, what percentage of revenues has to be replaced by new product or through reregistration of existing product as it comes through, please?
Gregory Hunt
executiveOkay, Grant, there's quite a bit there, so let me try to take it piece by piece. When we look at the regulatory outs we're aware of for financial year '22, they're probably around — probably EUR 15 million. But as I mentioned earlier, we believe what we have in our current portfolio will largely offset that. Looking ahead to '23, '24, '25, it remains very uncertain, since we do have the option to defend those molecules if we choose to. And at this stage it's simply too early for us to make that decision. That's the impact in '22. For '23, '24, '25, it's much more difficult. What we do know is that the Sumitomo products that are due and currently on track for launch in '24 give us a pretty significant step up for some of the products we see in our current portfolio. And the confidence around those products getting registered will then shape our thinking about what we defend and what we don't defend in the current portfolio.
Grant Saligari
analystAll right, that clears things up. And I just want to make sure — so the EUR 15 million figure, that's revenue?
Gregory Hunt
executiveYes — the margin figure.
Grant Saligari
analystRegarding margin, let's turn to the gross profit figure.
Gregory Hunt
executiveAbsolutely.
Grant Saligari
analystAlright, got it. That helps. And if I could just ask a second question. On the updated dividend policy — I wasn't really focused on whether you gave a percentage of free cash flow. But I'm curious whether there is any — whether you did or didn't, could you say more about that, please?
Paul Townsend
executiveYeah. No, Grant, we didn’t. Essentially, what we’re saying is that this ties to cash flow. So if there isn’t positive cash flow, then it wouldn’t be considered, except that we had room under our leverage. So there are 2 gateways, so to speak. One is that positive cash flow, and the other one is leverage as well.
Grant Saligari
analystAll right, then how are we supposed to view the dividend payout ratio from here on out? With no particular percentage in mind, should we just lean on the NPAT figure, applying something like a free cash flow filter to it?
Paul Townsend
executiveI think it really comes down to — and I suppose this ties back to capital management, potentially. So what we're aiming for — if we can aim for breakeven at a low point in the cycle. In theory, then, we're always seeking to be cash flow positive, and then it will be relative — there's a dividend policy that we're not being public on regarding a percentage, but we don't want to communicate that because we want to retain discretion as to how we go about it. But it will — all I'm going to say is that it is absolutely linked to cash flow. So there isn't an impact, rather. And the other aspect is we'll be looking at in leverage. So I know that's probably not helpful in how you model what dividends may be, I guess, in the future. But we want to be very strict in ensuring that the cash flow line and the leverage line are taken into consideration.
Operator
operatorAlexander Patent from Citi has the next question.
Alex Paton
analystAnd yeah, congratulations on turning the earnings around. It’s nice to see. Right now it looks like every pesticide active ingredient is moving upward because of the energy situation in China. Are there any non-herbicide ingredients where you’re concerned you won’t be able to push price increases through? I’m just thinking about what happened with tebuconazole and prochloraz a year or 2 ago. Could that kind of pressure happen again?
Gregory Hunt
executiveNo. Part of the squeeze we faced two years back came from the supplier — if you recall that well-known explosion. Really, it amounted to the factory shutting down. As a result, we simply had no way to obtain the product. I mean, product is being made now and moving, though currently, because of power curbs we're observing in certain parts of China — chiefly the Eastern seaport and the more heavily populated regions — we're seeing plants operating at 50% and 60% of capacity. That comes about because of the power restrictions. And we'd anticipate that after Chinese New Year, after the Beijing Olympics, the Winter Olympics, and after winter in the Northern Hemisphere, we'd anticipate the supply situation coming out of China to get better. So we aren't seeing — on those higher-value products, we aren't seeing a problem. What's really the problem today is the high-volume herbicide products.
Alex Paton
analystRight. And I'd assume those are simpler to push price hikes through on right now, particularly with the demand being what it is.
Gregory Hunt
executiveRight, and that’s honestly where the attention sits once you get into the burn-down — as preparation for cropping begins, the strain falls squarely on those herbicide products.
Alex Paton
analystUnderstood. And on that note, given how sharply glyphosate prices have risen, have you noticed a corresponding lift in 2,4-D sales? Or is there any substitution by growers toward your other chemicals as a reaction to that price jump?
Gregory Hunt
executiveYes. Demand for 2,4-D and MCPA is definitely rising, no question about it. Both <<inaudible>>
Operator
operatorOur following question is from Richard Johnson at Jefferies.
Richard Johnson
analystGreg, I'd like to open by asking about growth across the coming year or 2. You've partly addressed this already. But suppose — purely hypothetically, and assuming seasonal conditions showed no year-on-year change — where should we expect you might generate growth, if anywhere? Profit growth, that is.
Gregory Hunt
executiveYes, yes, I hear the question. Well, I suppose the simplest approach is to go region by region. Look, there could be — there's definitely growth in Asia. In Australia, though, I think it's simply too soon right now. We're really only 6 weeks in. The summer crop outlook looks favorable. As for the winter crop, it's genuinely too early to say. We've benefited from sharp rises in commodity products over the last 6 months. And that could turn around fast in the second half should prices drop quickly. And I believe logistics challenges will persist. So repeating what we did this year in Australia will be difficult — not impossible, but for the reasons I just gave, difficult. I do believe there's growth in North America. We expect increased plantings. Demand is very strong at the moment. The problem is getting access to supply. So yes, we see growth in North America. In Europe, as I mentioned, I think we can offset the regulatory losses from what's currently in our portfolio, and particularly the acquired portfolios. There are a few gems in there.
Gregory Hunt
executiveMoving to seeds, as Brent mentioned, demand is solid in the base seeds business — canola, sorghum and sunflower in particular are showing positive momentum. So I do see some upside there. There will probably be something from carinata in '22. But honestly, looking beyond '22, I see very strong growth coming out of the seeds portfolio, both in carinata and omega-3 nutraceuticals. And there's no reason why, over the longer term, we wouldn't see more growth coming in Australia, and that will largely come from the portfolio. So I've tried to give you a bit of a feel for '22, but we're really thinking about medium- to longer-term growth. And we see a good runway in the portfolio we've got coming over the next 2 to 5 years. And pretty significant upside in the seeds portfolio.
Richard Johnson
analystUnderstood, that's quite useful. Then just two technical points. Regarding the software adjustment—the accounting adjustment—is there any basis for expecting that adjustment to differ in magnitude as we move forward?
Paul Townsend
executiveNope. Year over year, that figure would stay identical.
Richard Johnson
analystThanks. Last thing, Paul — could you walk me through how the tax charge plays out in the second half?
Paul Townsend
executiveYes. Absolutely. So essentially, during the first half we recorded an effective tax rate of roughly 39%. And I think APAC performed better than our expectations at that point, which let us recognize losses that were, so to speak, not on the balance sheet. So we could take losses that were sitting on the balance sheet, and that gave us a lower provided — if you will, it produced a better tax position there. Then in Europe, we saw a different movement in profits. So there was a shift, for instance, among certain countries where booking losses isn't possible — profits moved into countries where we were able to book losses or actually had profits. So Australia being in a position to claim a tax credit for unbooked losses, and Europe seeing profits shift or trading performance move between countries, allowed us to bring the rate down.
Richard Johnson
analystUnderstood. So what's the right way for us to frame that for this year?
Paul Townsend
executiveThat's essentially the signal. Over the medium term, we expect that tax rate to remain at that level.
Richard Johnson
analystAll right, will that yearly rate hold steady from here on out?
Paul Townsend
executiveYes. It might move between the two halves, but for the whole year, that's how I see it.
Operator
operatorOur following question is from Evan Karatzas of UBS.
Evan Karatzas
analystGreg and Paul, regarding those price increases you're pushing through, could you perhaps speak to how much of a revenue boost price provided, in percentage terms? And if you can, what price expectation should we have for FY '22?
Paul Townsend
executiveYeah, Evan, honestly, that's a topic we'd rather not get into — we're pretty sensitive about it. What I can tell you, though, is that Greg's remark there concerns our capacity to keep prices where they are, considering the cost pressures we're facing right now.
Evan Karatzas
analystYes, that's reasonable. And likewise on the cost-reduction initiative, you said you've now achieved $25 million. Could you perhaps give us some detail on the benefits anticipated for FY '22? And also, which regions will those efforts concentrate on?
Paul Townsend
executiveYes. Well, Evan, I think we’re probably finished now on those regarding the $25 million—as we mentioned, the analysis was maybe $20 million this year. So that should more or less stay the same, but nothing additional will come beyond FY ’20—between FY—past FY ’21. So what we’re attempting to do there—and that is essentially SG&A, with $15 million of it in Europe—is basically, or our goal is, to truly keep our SG&A flat except for volume growth, where we have, clearly, freight—and there have also, clearly, been some freight pressures from COVID and similar factors, as we noted.
Evan Karatzas
analystAlright, and sorry, one last thing, perhaps for Brent. Just regarding carinata — demand is strong for SAF and low-carbon fuels. But Brent, I suppose what's the expected timing before it becomes a meaningful driver for freight? Or, to put it another way, how much of that Argentina expansion is prepared for commercial sale, and what kind of volume increase will that provide?
Brent Zacharias
executiveYes. Thanks, Evan. Yeah, I suppose just to give that some context — our carinata program is commercial already, and we're quite happy with what we've managed to accomplish in a brief period since acquiring it. The main focus at present, as you pointed out, is that this is now the expansion stage of it. And while we're concentrating on '22 expansion out of Argentina. And I think, as we mentioned, the launch of one of the hybrid technologies ought to accelerate that adoption. At the same time, we're doing development work in other nations to grow beyond Argentina. So we will keep seeing sales and margin growth annually as we move forward, including in '22. But I suppose, really, when we think about the second part of your question, the materiality of that, we truly see 2023 and 2024 as years in which we really begin to reach greater scale, both through the launch of our hybrids and through expansion into other countries.
Operator
operatorJames Ferrier of Wilsons has the next question.
James Ferrier
analystFirst question — I'd like to get a bit more color on how the sales growth for FY '21 breaks down, specifically around volume, mix, and price. So I understand that on a constant currency basis, overall growth came in at 19%. FX was clearly a headwind to that. But if you could offer a little extra detail on the other drivers — volume, price, and mix — within that 19% constant currency growth.
Paul Townsend
executiveYeah. James, on that particular point, it's probably — the split between the two is somewhat difficult given the reasons, and what we can say is pretty much that a lot of it has been tied to pricing, with volumes up a bit but not as significant as pricing is. So the relative mix would be more pricing and less volume — somewhat higher pricing would be, if you like, the main drivers.
James Ferrier
analystAll right, that clears things up. And by price, do you mean you're raising your own prices? Or does that simply reflect reduced discounting compared with what a typical year would bring, given the demand and supply dynamics we witnessed last year?
Paul Townsend
executiveIt's the first of those.
James Ferrier
analystYes. For my second question, I just want a quick clarification on the trade finance facility. So if I understand the annual report correctly, the securitized payables show $297 million and the securitized receivables show $18 million. And am I correct that both of those are still off balance sheet facilities?
Paul Townsend
executiveCorrect. The receivables are in fact unwinding, so that won’t be a fatal item anymore. The $18 million is actually coming off as we speak, and most of that is New Zealand receivables. On the supply financing piece, it remains off balance sheet. As I mentioned during the conference call, we expanded it because of price. Clearly, as raw material costs have risen, pricing has moved higher. So we needed to enlarge that facility and into the port to secure our supply, since the Chinese suppliers benefit from the terms it provides them.
James Ferrier
analystYeah. Yeah. Got it. That’s clear. And last thing, just regarding CapEx—you may have mentioned this, and I likely heard it wrong. But in the CapEx guidance for FY ’22, could you break it down between PPE and what you’re investing in R&D across chem and seeds?
Paul Townsend
executiveYeah. Let me frame it like this. Out of that total of $190 million, roughly $100 million falls under portfolio or investment in intangibles — excuse me. Within that $100 million, crop protection accounts for around $60 million, and seeds make up about $40 million. As for PP&E, it comes to roughly $45 million, on what you'd describe as the staying business, while the remainder is largely growth. I believe I mentioned $35 million as being right. So that gives you the rough breakdown, so to speak. Those growth projects — and when I say growth, they're projects that return profit, projects that retain cash flow.
Operator
operatorJonathan Snape from Bell Potter has the next question.
Jonathan Snape
analystOnly a couple. The first is for Greg. Regarding the — I believe you want to flag a note containing an inventory write-off charge of about $16 million. And I was attempting to determine whether a figure for the PPE was included there. My assumption is that it has been captured in the headline results.
Gregory Hunt
executiveJonathan, is that charge correct?
Jonathan Snape
analystRight. And did a material one actually happen last year? I couldn't locate one. My understanding is we provided 2 months of side-by-side support in the ordinary course of business — or is that something different?
Gregory Hunt
executiveYes. Could we follow up with you on that regarding the comparative, specifically on a pro forma comparative basis? That said, this falls within the normal course of business.
Jonathan Snape
analystAlright. Alright. And regarding omega-3, did oil sales contribute at all to the seeds business this year in terms of performance? Or is that still initially being offset against capitalized costs?
Gregory Hunt
executiveBrent?
Brent Zacharias
executiveYeah, Jonathan, I’ll handle that question. As for recognizing revenue and margin from that business this year—yes, we’ve accomplished that, if that’s what you’re asking.
Jonathan Snape
analystYes. Was anything material in this year's figure, though? Since you're clearly restarting the program, obviously. You've signed up — I believe you have 8 additional customers. I'm trying to work out how to talk about omega-3 going into, I suppose, the contribution this year? And then, with commercial plantings starting up again, how should we begin thinking about it for '22 and '23?
Brent Zacharias
executiveYes. Yes. Looking at it from the standpoint of earnings contribution, it isn't material in the current year, but we have to keep at it — especially in the latter part of the second half — and get much stronger sales conversion of that technology. And I think the second part of your question is that as we look out to FY '22, we'll continue running off the inventory we have and that we produced in 2020. As we've mentioned, we'll be producing — back into producing omega-3 with followers in calendar '22, which we think will fit pretty nicely with the inventory available toward the end of calendar '22 to really start having some of the impact into 2023. Like we've said, the recovery we're seeing in our markets is really encouraging. We still think it could take another 12 months before we see the full pricing and margin recovery of our customers. But at this stage, we're really pleased with what we've seen in the last few months, and that's how we're planning accordingly.
Operator
operatorGrant Saligari from Credit Suisse has a follow-up question coming next.
Grant Saligari
analystSomething I was just noticing — going through the annual report, is it still the case that 36% of employees are in Europe? If I look at — I understand there are big manufacturing facilities in Europe. But do you think that's sort of the right allocation of people, just sort of thinking about where the revenue and profit of the business is generated, and how might that sort of change over time?
Gregory Hunt
executiveMy apologies, Grant—I'm still trying to tune in to where you're coming from. Could you make that comment once more?
Grant Saligari
analystYes. In — in your report, the breakdown of where people sit within the organization, and 36% of employees, I think if I'm reading it right, are located in Europe, which seems like a fairly heavy allocation of employees to that segment, or perhaps I'm really getting it correctly.
Gregory Hunt
executiveYeah. Well, I’m not sure. I haven’t run that analysis. But I suppose, when I consider that 46% of our earnings come out of the European business, I guess that doesn’t surprise me.
Operator
operatorWe have no more questions right now, and with that our conference today comes to an end. We appreciate everyone joining in. You’re welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.